STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.